Article
KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s disease
2020-07-07
Abstract excerpt
<h4>Background and Purpose</h4> Monoamine oxidase-B (MAO-B) is a long-standing therapeutic target for Parkinson’s disease (PD), however, previous clinical studies demonstrated discouraging effects of currently available irreversible MAO-B inhibitors. Since KDS2010, a novel, potent, selective, and reversible MAO-B inhibitor, has been developed, here we tested its therapeutic potential in animal models of PD. <h4>E...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- dff67ac8-6386-51c2-b50d-b561c89d8246
- DOI
- 10.1101/2020.07.06.190579
